Avanos Medical Taken Private by AIP for $1.27B: What the PE Take-Private Deal Means for MedTech

The Deal at a Glance

On April 14, 2026, Avanos Medical, Inc. (NYSE: AVNS) announced it had entered into a definitive agreement to be acquired by affiliates of American Industrial Partners (AIP) in an all-cash transaction valued at approximately $1.272 billion. The deal takes Avanos private after more than a decade as a publicly traded company following its 2014 spinoff from Kimberly-Clark.

Under the terms of the agreement, unanimously approved by Avanos's board of directors, stockholders will receive $25.00 per share in cash. The $25.00 price represents a 72.1% premium to the company's closing stock price on April 13, 2026 (the last full trading day before the announcement) and an 82.8% premium to the 30-day volume-weighted average share price.

The transaction is expected to close in the second half of 2026, subject to stockholder approval, expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period, and other customary regulatory clearances. There is no financing condition. Upon completion, Avanos will become a privately held company and its common stock will be delisted from the New York Stock Exchange. Avanos will remain headquartered in Alpharetta, Georgia.

The Players

Avanos Medical

Avanos Medical is a medical technology company focused on two clinical segments: Specialty Nutrition Systems and Pain Management & Recovery. The company's products are designed to improve patient outcomes and reduce the cost of care, with a particular emphasis on non-opioid pain management and enteral nutrition delivery.

The company traces its origins to Kimberly-Clark Corporation's healthcare division, which produced medical devices and surgical products. Key milestones in the company's history:

Avanos sells its products in more than 90 countries and operates manufacturing facilities in the United States, Mexico, and Canada. The company employs approximately 5,000 people.

The three-year transformation plan initiated in 2023 focused on commercial optimization, innovation investment, supply chain efficiency, and financial improvements, targeting over 60% gross margins. The divestitures of the Surgical & Infection Prevention and Respiratory Health businesses simplified Avanos's portfolio to two focused franchises.

American Industrial Partners (AIP)

American Industrial Partners is an operationally oriented private equity firm with approximately $17.5 billion in assets under management. Founded in 1989, AIP makes control investments in industrial businesses serving domestic and global markets, with deep roots in the industrial economy and experience across three economic cycles.

AIP invests in all forms of corporate divestitures, management buyouts, recapitalizations, and going-private transactions of established businesses with sales greater than $500 million. The firm has completed over 145 platform and add-on acquisitions. Current AIP portfolio companies span sectors including manufacturing, energy, materials, aerospace, and now healthcare.

While AIP is primarily known as an industrials investor, the Avanos acquisition fits its strategy of identifying established businesses with strong market positions, proven management teams, and opportunities for operational improvement. AIP partners Joel Rotroff and Sunny Li emphasized the company's "strong positions in attractive categories" and "compelling platform for continued growth."

The Avanos deal came just nine days before AIP announced its acquisition of Honeywell's Warehouse and Workflow Solutions business on April 23, 2026, demonstrating the firm's active dealmaking pace.

Avanos's Product Portfolio

Specialty Nutrition Systems

Avanos's Specialty Nutrition Systems franchise provides enteral feeding solutions for patients from neonates through geriatric populations. The product portfolio is anchored by several well-established brands:

MIC-KEY Low-Profile Feeding Tubes — One of the most widely recognized enteral feeding tube brands globally. MIC-KEY tubes are low-profile gastrostomy feeding devices designed for long-term enteral nutrition access. The low-profile design sits flush against the skin, improving patient comfort, reducing visibility, and lowering the risk of tube displacement compared to traditional dangling feeding tubes.

CORTRAK 2 Enteral Access System — An FDA-cleared electromagnetic-guided feeding tube placement system that enables clinicians to confirm nasogastric and nasoenteric tube placement at the bedside without fluoroscopy or X-ray confirmation. CORTRAK 2 saves time for nurses, dietitians, and GI/ICU physicians by reducing the need for radiographic confirmation and enabling faster initiation of enteral nutrition.

NEOMED Neonatal Solutions — A comprehensive portfolio of neonatal-specific products including feeding tubes, oral care/colostrum kits, urinary catheters, and lumbar puncture trays designed for the smallest and most vulnerable patients. The neonatal segment is a high-growth area as advances in neonatal intensive care improve survival rates for premature infants who require specialized nutritional support.

CORFLO and CORGRIP Feeding Tubes — Standard and securement feeding tubes for adult and pediatric patients requiring enteral nutrition access across various clinical settings.

The enteral nutrition market is driven by aging populations, increasing prevalence of chronic diseases requiring nutritional support, growing premature birth rates, and expanding home healthcare. Enteral feeding is a vital lifeline for patients who cannot consume adequate nutrition orally, spanning conditions from cancer and neurological disorders to critical illness and prematurity.

Pain Management & Recovery

Avanos's Pain Management & Recovery franchise provides non-opioid solutions for managing both chronic and post-surgical pain:

ON-Q Elastomeric Pain Pumps — Non-opioid continuous regional anesthesia delivery systems that provide continuous infusion of local anesthetics to surgical wound sites or near nerves for postoperative pain management. ON-Q pumps are single-use, portable devices that provide pain relief for up to five days after surgery without systemic opioids. Under the NOPAIN Act, CMS expanded reimbursement to include ON-Q and ambIT infusion pumps — notably, these are the only infusion pain pumps included under the legislation, giving Avanos a significant reimbursement advantage.

COOLIEF Cooled Radiofrequency System — A cooled radiofrequency ablation system for chronic pain management. COOLIEF combines radiofrequency energy with controlled cooling to create larger, more effective lesions for treating chronic pain conditions including osteoarthritis of the knee, chronic lower back pain, and other musculoskeletal conditions. The cooled RF approach allows treatment of larger nerve areas while protecting surrounding tissue.

Game Ready Cryo-Compression Therapy — A dynamic compression and cold therapy system used for post-surgical recovery and injury rehabilitation. Game Ready combines intermittent pneumatic compression with circumferential cold therapy to reduce pain, swelling, and recovery time following orthopedic surgery and sports injuries.

ambIT Electronic Pain Pumps — Electronic infusion pump systems for continuous regional anesthesia delivery, complementing the ON-Q elastomeric pump line with programmable delivery options.

The non-opioid pain management market is one of the strongest growth segments in medical devices, driven by the opioid crisis, regulatory mandates, and payer policies that increasingly favor non-pharmacological pain interventions. The NOPAIN Act (Non-Opioids Prevent Addiction in the Nation Act), which took effect in 2025, requires CMS to provide separate reimbursement for certain non-opioid pain management devices used in surgical settings — directly benefiting Avanos's ON-Q and ambIT products.

The Strategic Rationale

Why AIP Acquired Avanos

Several factors make Avanos an attractive private equity target:

1. Established brands with market-leading positions. Avanos's MIC-KEY, ON-Q, COOLIEF, and Game Ready brands hold #1 or #2 market positions in their respective categories. These are not commodity products — they are clinically differentiated devices with strong brand recognition among healthcare providers.

2. Favorable market tailwinds. Both of Avanos's segments benefit from secular growth drivers: aging populations and chronic disease prevalence for nutrition systems, and the opioid crisis and NOPAIN Act for pain management. These trends are structural, not cyclical.

3. Reimbursement catalyst. The NOPAIN Act provides separate Medicare reimbursement for ON-Q and ambIT infusion pumps, removing a historical barrier to adoption and creating a direct revenue growth driver. This type of legislative reimbursement catalyst is relatively rare and highly valuable.

4. Portfolio simplification completed. Avanos's divestitures of Surgical & Infection Prevention (2017) and Respiratory Health (2023) have already done the hard work of portfolio simplification. AIP acquires a focused two-segment company rather than a conglomerate requiring restructuring.

5. Margin improvement opportunity. Avanos's transformation plan was targeting over 60% gross margins. As a private company with AIP's operational expertise in lean manufacturing, supply chain optimization, and engineering effectiveness, there is room to accelerate margin expansion.

6. Discounted public market valuation. The 72% premium AIP paid reflects the degree to which Avanos was undervalued as a small-cap public company. The take-private premium, while significant, may still represent value creation potential for AIP given the underlying business fundamentals.

Why Avanos Accepted

From Avanos's perspective, the deal delivers immediate and certain value to stockholders at a substantial premium. The 72.1% premium to the closing price and 82.8% premium to the 30-day VWAP represent a compelling exit for a company whose stock had struggled to reflect the underlying value of its franchises.

The transaction also removes the cost and burden of public company compliance, including Sarbanes-Oxley requirements, SEC reporting, analyst coverage expectations, and quarterly earnings pressure. As a private company, Avanos can invest in longer-term growth initiatives without the short-term earnings scrutiny of public markets.

The NOPAIN Act: A Critical Tailwind

The Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act is perhaps the most important legislative tailwind for Avanos's Pain Management & Recovery segment. Key provisions:

• Separate reimbursement — CMS provides separate Medicare Part B payment for non-opioid pain management devices used during and immediately after surgery, rather than bundling these costs into the surgical procedure payment
• ON-Q and ambIT specifically included — CMS has confirmed that ON-Q and ambIT infusion pumps are among the only infusion pain pumps covered under the NOPAIN Act, giving Avanos a differentiated reimbursement position
• Removes adoption barriers — Before the NOPAIN Act, hospitals had limited financial incentive to use non-opioid pain devices because the cost was bundled into the overall surgical DRG payment. Separate reimbursement creates a direct financial incentive for adoption
• Market expansion potential — The NOPAIN Act makes non-opioid pain management devices economically viable for a broader range of hospitals and surgical centers, expanding the addressable market

The NOPAIN Act is a legislative example of how the opioid crisis is reshaping medical device markets. As policymakers seek to reduce opioid prescriptions, medical devices that provide effective non-pharmacological pain relief receive increasing regulatory and reimbursement support.

Private Equity in MedTech: The Bigger Picture

The PE Take-Private Trend

The Avanos acquisition is part of a broader trend of private equity firms acquiring publicly traded medical device companies and taking them private. Several factors are driving this trend in 2026:

1. Record dry powder. PE firms globally hold over $1 trillion in uncalled capital commitments, creating pressure to deploy capital into quality assets.

2. Public market dislocation. Small and mid-cap medical device companies often trade at discounts to their intrinsic value due to limited analyst coverage, low trading volumes, and investor preference for large-cap names. This creates attractive take-private opportunities.

3. Operational value creation. PE firms like AIP, with deep operational expertise in lean manufacturing, supply chain optimization, and engineering effectiveness, can create value in medical device companies through operational improvements rather than financial engineering alone.

4. Favorable exit environment. Medtech M&A activity remains robust in 2026, with both strategic acquirers and PE firms competing for quality assets. This gives PE firms confidence in eventual exit pathways.

Other Recent PE MedTech Deals

The Avanos deal adds to a growing list of PE transactions in the medical device space:

AIP's entry into medical devices with the Avanos acquisition may signal growing PE interest in established medical technology companies with strong brands, defensible market positions, and secular growth tailwinds — particularly as healthcare continues to represent a growing share of GDP in developed economies.

Risks and Considerations

Integration Risk

AIP is primarily known as an industrials investor. While the firm brings operational expertise in manufacturing optimization and supply chain management, healthcare presents unique challenges including FDA regulatory compliance, clinical evidence requirements, and hospital procurement dynamics that differ from traditional industrial markets. AIP's ability to navigate these healthcare-specific complexities while applying its operational playbook will be a key determinant of value creation.

Regulatory Scrutiny

The transaction requires Hart-Scott-Rodino Act review. Given the deal size ($1.272 billion) and the absence of significant market overlap between AIP's existing portfolio companies and Avanos's medical device business, regulatory approval is expected to proceed without major obstacles.

Debt Load

While the press release states there is no financing condition, the acquisition will likely increase Avanos's debt load under AIP's ownership. Higher leverage can limit future investment flexibility and increase interest expenses, though AIP's strategy typically emphasizes operational improvement rather than aggressive leverage.

Competitive Dynamics

In enteral feeding, competitors include Fresenius Kabi, Cardinal Health, and various specialty manufacturers. In non-opioid pain management, the competitive landscape includes Pacira BioSciences (Exparel), B. Braun, and a growing number of device-based pain management companies. AIP will need to invest in product innovation and clinical evidence to maintain Avanos's competitive positions.

What This Means for the Industry

For Medical Device Companies

1. PE is an increasingly viable alternative to strategic M&A. The Avanos deal demonstrates that operationally focused PE firms are willing to pay significant premiums for established medtech companies, providing an alternative to acquisition by larger strategic buyers.

2. The take-private premium is real. Small and mid-cap medtech companies trading at public market discounts may find that PE firms are willing to pay 70–80%+ premiums to unlock value. This creates optionality for boards considering strategic alternatives.

3. Portfolio focus is rewarded. Avanos's deliberate portfolio simplification — divesting non-core businesses to focus on two high-growth segments — made the company more attractive to PE buyers. Companies considering similar simplification should take note.

For Hospitals and Health Systems

1. Continuity likely. AIP has stated that Avanos will remain headquartered in Alpharetta, Georgia, and will continue operating under the Avanos name. Hospital customers should expect product continuity, though pricing and contracting strategies may evolve under private ownership.

2. Potential for increased investment. PE ownership may bring increased investment in R&D, manufacturing, and commercial capabilities as AIP seeks to grow the business and improve margins.

For Patients

1. Non-opioid pain options expanding. The combination of NOPAIN Act reimbursement, PE-backed investment in commercial capabilities, and growing clinical adoption of non-opioid pain management devices means patients will have increasing access to effective pain relief without opioids.

2. Enteral nutrition innovation continues. The neonatal and pediatric nutrition market, in particular, benefits from continued investment in products like MIC-KEY and NEOMED that serve vulnerable patient populations.

Key Takeaways

• American Industrial Partners (AIP) agreed to acquire Avanos Medical for $1.272 billion on April 14, 2026, in an all-cash going-private transaction at $25.00 per share — a 72.1% premium to the prior day's closing price
• Avanos operates two focused segments: Specialty Nutrition Systems (MIC-KEY, CORTRAK 2, NEOMED feeding tubes) and Pain Management & Recovery (ON-Q pumps, COOLIEF cooled RF, Game Ready)
• The NOPAIN Act provides separate Medicare reimbursement for Avanos's ON-Q and ambIT infusion pumps, creating a significant revenue growth catalyst for the non-opioid pain management franchise
• Avanos was originally spun off from Kimberly-Clark in 2014 as Halyard Health and systematically divested non-core businesses to become a focused two-segment medical device company
• AIP, with $17.5 billion in AUM, is primarily an industrials investor; the Avanos deal represents its entry into medical technology, leveraging its operational expertise in manufacturing optimization
• The deal is expected to close in H2 2026 pending stockholder approval and regulatory clearances, with no financing condition
• The transaction reflects a broader PE trend of taking undervalued small-cap medtech companies private to unlock value through operational improvement, portfolio focus, and investment in growth initiatives